

## antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
chloroquine and derivatives	4 studies <sup>1</sup>	0.93 [0.48 ; 1.81], 1 study, I2=0% inconclusive result	-	0.84 [0.59 ; 1.20], 3 RCTs, I2=0% inconclusive result	-
ivermectin	3 studies <sup>2</sup>	-	1.51 [0.54 ; 4.24], 1 RCT, I2=0% inconclusive result	0.85 [0.50 ; 1.46], 2 RCTs, I2=0% inconclusive result	0.52 [0.10 ; 2.58], 1 study, I2=0% inconclusive result
lopinavir/ritonavir	2 studies <sup>3</sup>	-	1.31 [0.94 ; 1.83], 1 RCT, I2=0% inconclusive result	0.81 [0.65 ; 1.03], 2 RCTs, I2=0% inconclusive result	-
azithromycin	1 study <sup>4</sup>	-	0.74 [0.51 ; 1.07], 1 RCT, I2=0% inconclusive result	1.08 [0.79 ; 1.47], 1 RCT, I2=0% inconclusive result	-
favipiravir	1 study <sup>5</sup>	-	-	1.61 [0.73 ; 3.58], 1 study, I2=0% inconclusive result	-
Lopinavir/ritonavir plus hydroxychloroquine	1 study <sup>6</sup>	-	0.63 [0.37 ; 1.06], 1 RCT, I2=0% inconclusive result	0.58 [0.36 ; 0.93], 1 RCT, I2=0% certainty unassessable	-
remdesivir	1 study <sup>7</sup>	0.95 [0.55 ; 1.64], 1 RCT, I2=0% inconclusive result	1.23 [0.87 ; 1.74], 1 RCT, I2=0% inconclusive result	1.10 [0.49 ; 2.45], 1 RCT, I2=0% inconclusive result	-
sofosbuvir and daclatasvir	1 study <sup>8</sup>	-	-	0.12 [0.02 ; 0.62], 1 study, I2=0% certainty unassessable	-

## Notes

<sup>1</sup>HYDRA (Hernandez-Cardenas), 2021 (NCT04315896) ; REMAP-CAP-HCQ, 2020 (NCT02735707) ; Mahevas, 2020 ( ) ; Yu, 2020 ( )

<sup>2</sup>Galan, 2021 (RBR-8h7q82) ; Okumus, 2020 (NCT04646109) ; Camprubi, 2020 ( )

<sup>3</sup>Cao, 2020 (ChiCTR2000029308) ; REMAP-CAP (lopinavir/ritonavir only), 2020 (NCT02735707)

<sup>4</sup>COALITION II Covid-19 Brazil (Furtado), 2020 (NCT04321278)

<sup>5</sup>Kocayigit H, 2020 ( )

<sup>6</sup>REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 (NCT02735707)

<sup>7</sup>CAP-China (Wang et al.), 2020 (NCT04257656)

<sup>8</sup>Eslami, 2020 (IRCT20200324046850N2)